Table 3.

Comparison of National Institutes of Health Stroke Scale scores of acute cerebral infarction patients between the cattle encephalon glycoside and ignotin (CEGI) group and the placebo group on days 7, 14, and 90 after treatment

		Mild stroke subgroup		t-value	P-value	Moderate stroke subgroup		t-value	P-value
		CEGI group	Placebo group			CEGI group	Placebo group
FAS analysis	Days 7	4.85±1.59	4.71±1.73	–0.52	0.605	7.22±2.55	9.17±6.98	–1.5	0.145
	Days 14	3.04±1.68	3.36±1.69	–1.1	0.272	4.42±2.48	7.27±7.52	–2.05	0.049*
	Days 90	2.08±1.72	2.49±1.83	–1.36	0.174	3.05±1.96	5.21±2.93	–3.75	< 0.001**
PPS analysis	Days 7	4.88±1.61	4.73±1.75	0.5	0.621	7.2±2.56	7.93±1.78	–1.73	0.089
	Days 14	3.05±1.67	3.31±1.68	–0.88	0.38	4.42±2.48	5.93±2.46	–2.85	0.005**
	Days 90	2.09±1.7	2.49±1.79	–1.32	0.188	2.98±1.9	5.21±2.99	–3.76	< 0.0001**

Data are expressed as the mean ± SD. *P < 0.05, **P < 0.01 (rank-sum test and independent t-test). The full analysis set (FAS) in the mild stroke subgroup consisted of 122 and 48 cases in the CEGI and placebo groups, respectively; in the moderate stroke subgroup it consisted of 107 cases in the CEGI group and 30 cases in the placebo group. The per-protocol set (PPS) in the mild stroke subgroup consisted of 114 cases in the CEGI group and 45 in the placebo group; in the moderate stroke subgroup it consisted of 104 cases in the CEGI group and 28 cases in the placebo group.